Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder

Next Previous
Trial Profile

A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levomilnacipran (Primary) ; Fluoxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors AbbVie; Allergan

Most Recent Events

  • 01 Jun 2024 Primary endpoint has not been met (Change From Baseline in Childrens Depression Rating Scale- Revised (CDRS-R)) , according to Results published in the Journal of Child and Adolescent Psychopharmacology
  • 01 Jun 2024 Results published in the Journal of Child and Adolescent Psychopharmacology
  • 02 Mar 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top